Science and Research

COPD: the patient perspective

Chronic obstructive pulmonary disease (COPD) is a highly prevalent disease characterized by nonreversible airway obstruction. Well-characterized symptoms such as exertional dyspnea and fatigue have a negative impact on patients' quality of life (QoL) and restrict physical activity in daily life. The impact of COPD symptoms on QoL is often underestimated; for example, 36% of patients who describe their symptoms as being mild-to-moderate also admit to being too breathless to leave the house. Additionally, early morning and nighttime symptoms are a particular problem. Methods are available to allow clinicians to accurately assess COPD symptoms, including patient questionnaires. Integrated approaches to COPD management, particularly pulmonary rehabilitation, are effective strategies for addressing symptoms, improving exercise capacity and, potentially, also increasing physical activity. Inhaled bronchodilators continue to be the mainstay of drug therapy in COPD, where options can be tailored to meet patients' needs with careful selection of the inhaled medication and the device used for its delivery. Overall, an integrated approach to disease management should be considered for improving QoL and subsequent patient outcomes in COPD.

  • Jones, P. W.
  • Watz, H.
  • Wouters, E. F.
  • Cazzola, M.

Keywords

  • Bronchodilator Agents/*therapeutic use
  • Cost of Illness
  • Exercise Tolerance/drug effects
  • Health Status
  • Humans
  • Lung/*drug effects/physiopathology
  • *Patient-Centered Care
  • Predictive Value of Tests
  • Pulmonary Disease, Chronic Obstructive/diagnosis/*drug
  • therapy/physiopathology/psychology
  • Quality of Life
  • Recovery of Function
  • Treatment Outcome
  • Copd
  • patients
  • physical activity levels
  • pulmonary rehabilitation
Publication details
DOI: 10.2147/COPD.S85977
Journal: International journal of chronic obstructive pulmonary disease
Pages: 13-20 
Work Type: Review
Location: ARCN
Disease Area: COPD
Partner / Member: Ghd
Access-Number: 26937186
See publication on PubMed


chevron-down